Literature DB >> 2878694

A role for guanine ribonucleotides in the regulation of myeloid cell maturation.

D G Wright.   

Abstract

We have shown previously that induced maturation of the human myeloid leukemia cell line, HL-60, is associated with a selective down-regulation of guanine ribonucleotide synthesis and depletion of intracellular guanosine triphosphate (GTP) and guanosine diphosphate (GDP) pools. We showed, furthermore, that inhibitors of the enzyme, inosine monophosphate (IMP) dehydrogenase, which catalyzes the initial rate-limiting step of guanylate synthesis from the central intermediate IMP, are potent inducers of myeloid maturation in these cells. We now show that induced maturation of HL-60 cells is prevented or impaired if intracellular concentrations of guanine ribonucleotides are maintained at high levels. HL-60 cells can utilize exogenous guanine and guanosine to maintain GTP and GDP pools through a salvage pathway that bypasses guanylate synthesis from IMP. Moreover, incubation of HL-60 cells with guanosine or guanine (10(-6) to 10(-4) mol/L) prevents both the depletion of intracellular guanine ribonucleotides and the induction of myeloid maturation caused by the IMP dehydrogenase inhibitor, tiazofurin. These findings provide strong additional support for the concept that terminal myeloid differentiation is influenced by a guanine ribonucleotide-dependent regulatory system.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 2878694

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  9 in total

1.  Analysis of receptor-G protein interactions in permeabilized cells.

Authors:  T Wieland; K Liedel; S Kaldenberg-Stasch; D Meyer zu Heringdorf; M Schmidt; K H Jakobs
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1995-04       Impact factor: 3.000

2.  Cloning and functional characterization of GMPR2, a novel human guanosine monophosphate reductase, which promotes the monocytic differentiation of HL-60 leukemia cells.

Authors:  Jia Zhang; Weiping Zhang; Dajin Zou; Guoyou Chen; Tao Wan; Minghui Zhang; Xuetao Cao
Journal:  J Cancer Res Clin Oncol       Date:  2003-03-01       Impact factor: 4.553

3.  6-ethylmercaptopurine-mediated growth inhibition of HL-60 cells in vitro irrespective of purine salvage.

Authors:  D S Gibboney; B T French; D E Patrick; R W Trewyn
Journal:  Cancer Chemother Pharmacol       Date:  1989       Impact factor: 3.333

4.  Hematopoietic growth factor receptors.

Authors:  J H Shieh; M A Moore
Journal:  Cytotechnology       Date:  1989-12       Impact factor: 2.058

Review 5.  Physiological concentrations of purines and pyrimidines.

Authors:  T W Traut
Journal:  Mol Cell Biochem       Date:  1994-11-09       Impact factor: 3.396

Review 6.  Role of differentiation induction in action of purine antimetabolites.

Authors:  G Weber; Y Hata; N Prajda
Journal:  Pharm World Sci       Date:  1994-04-15

7.  Structural Dynamics in Ras and Related Proteins upon Nucleotide Switching.

Authors:  Rane A Harrison; Jia Lu; Martin Carrasco; John Hunter; Anuj Manandhar; Sudershan Gondi; Kenneth D Westover; John R Engen
Journal:  J Mol Biol       Date:  2016-10-14       Impact factor: 5.469

8.  Growth inhibition and induction of phenotypic alterations in MCF-7 breast cancer cells by an IMP dehydrogenase inhibitor.

Authors:  Y Sidi; C Panet; L Wasserman; A Cyjon; A Novogrodsky; J Nordenberg
Journal:  Br J Cancer       Date:  1988-07       Impact factor: 7.640

9.  Novobiocin-induced anti-proliferative and differentiating effects in melanoma B16.

Authors:  J Nordenberg; D Albukrek; T Hadar; A Fux; L Wasserman; A Novogrodsky; Y Sidi
Journal:  Br J Cancer       Date:  1992-02       Impact factor: 7.640

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.